-
Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval
Wednesday, May 3, 2017 - 2:41pm | 407Read More...Merck & Co., Inc. (NYSE: MRK) traders that haven't already done so should mark May 10 on their calendars. The company announced in early January the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab)....
-
Presidential Merck: 'Jimmy Carter' Oncology Drug Expected To Dominate, Hep C Drug Approved Across EU
Tuesday, September 13, 2016 - 3:36pm | 251Read More...Argus has lifted Merck & Co., Inc. (NYSE: MRK)'s EPS estimates for 2017 from $4.00 to $4.10 due to the company's strong drug pipeline. The analysts elaborated that the pipeline includes an expected increase in sales of Keytruda, a melanoma treatment drug used on President Jimmy Carter, which...
-
Merck's Q2 Good, But Not Good Enough, Says BMO
Monday, August 1, 2016 - 2:12pm | 471Read More...Despite topping the Street view, BMO said the second-quarter results of Merck & Co., Inc. (NYSE: MRK) is not "good enough" to change its Market Perform rating on the stock. Merck's quarterly revenue was about 1 percent above consensus and 1.5 percent above BMO's forecast, while EPS of $0.93 was...
-
Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term
Tuesday, April 12, 2016 - 10:06am | 368Read More...The first quarter earnings of Gilead Sciences, Inc. (NASDAQ: GILD) may miss the Street view, but promising Hep C Rx trends drive a positive outlook, according to a note from Baird. Analyst Brian Skorney said, "Our estimate for pro forma fully diluted EPS is $2.92 versus consensus at $3.12. We think...
-
Will Merck Encroach On Gilead's Harvoni Territory?
Tuesday, February 23, 2016 - 12:36pm | 363Read More...Slingshot Insights recently conducted an interview with Dr. Bruce Bacon, Professor of Internal Medicine at Saint Louis University School of Medicine about the impact that Merck & Co., Inc. (NYSE: MRK)’s Zepatier will have on the HCV market, particularly when it comes to Gilead Sciences...
-
Shares Of Merck Dip Lower Following Q4 Print
Wednesday, February 3, 2016 - 9:42am | 223Read More...Shares of Merck & Co., Inc. (NYSE: MRK) were trading lower by more than 2 percent early Wednesday morning after the company released its fourth quarter results. Merck earned $0.93 per share in the fourth quarter on revenue of $10.21 billion. Wall Street analysts were expecting the company...
-
Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient
Friday, January 29, 2016 - 12:29pm | 364Read More...Merck & Co., Inc. (NYSE: MRK) confirmed after Thursday's market close that the U.S. Food and Drug Administration has approved ZEPATIER for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection. Shares of Merck were trading higher by 1.32...
